More NewsRead More
Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin
August 27, 2015
Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical Trial of Tarloxotinib Bromide* (TH-4000) in Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC)
August 11, 2015
Threshold Pharmaceuticals Reports Second Quarter 2015 Financial and Operational Results
July 30, 2015
Threshold Pharmaceuticals Announces Presentation and Webcast at the Cantor Fitzgerald Healthcare Conference
July 01, 2015
Threshold Pharmaceuticals Presents Encouraging Preliminary Phase 2 Data in Multiple Myeloma at ASCO
May 31, 2015
Hot Stock: Threshold Pharmaceuticals, Shares Drop 5.5% (THLD)
September 28, 2015
Stocks Hitting 52-Week Highs
September 15, 2015
Stock to Watch: Threshold Pharmaceuticals Down 7.1% (THLD)
September 21, 2015
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here